Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitravatinib plus Pembrolizumab in advanced treatment-naïve PD-L1+ non-squamous NSCLC
NCT04925986Phase 2Terminated
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sitravatinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (4 arms). Primary endpoint: Objective Response Rate at 267 days. Started Feb 2022; status: terminated.
02
Drugs
sitravatinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04925986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04925986.